Related Experiment Video
Updated: Nov 22, 2025
A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG
Published on: March 7, 2017
Diffuse intrinsic pontine glioma: current insights and future directions
Dilakshan Srikanthan1,2,3, Michael S Taccone1,2,3,4, Randy Van Ommeren2,3,5
1Cell Biology Program, The Hospital for Sick Children, 686 Bay St, Toronto, ON, M5G 0A4, Canada.
Abstract:
Diffuse intrinsic pontine glioma (DIPG) is a lethal pediatric brain tumor and the leading cause of brain tumor-related death in children. As several clinical trials over the past few decades have led to no significant improvements in outcome, the current standard of care remains fractionated focal radiation. Due to the recent increase in stereotactic biopsies, tumor tissue availabilities have enabled our advancement of the genomic and molecular characterization of this lethal cancer. Several groups have identified key histone gene mutations, genetic drivers, and methylation changes in DIPG, providing us with new insights into DIPG tumorigenesis. Subsequently, there has been increased development of in vitro and in vivo models of DIPG which have the capacity to unveil novel therapies and strategies for drug delivery. This review outlines the clinical characteristics, genetic landscape, models, and current treatments and hopes to shed light on novel therapeutic avenues and challenges that remain.
Insights
Diffuse intrinsic pontine glioma (DIPG) is a deadly pediatric brain tumor. Advances in genomic characterization and new models offer hope for novel therapies against this challenging cancer.
Area of Science:
- Pediatric neuro-oncology
- Cancer genomics
- Tumorigenesis
Background:
- Diffuse intrinsic pontine glioma (DIPG) is a fatal pediatric brain tumor, causing most childhood brain tumor deaths.
- Current treatments offer limited efficacy, with fractionated focal radiation remaining the standard of care.
- Despite decades of research, significant improvements in patient outcomes have not been achieved.
Purpose of the Study:
- To review the clinical characteristics, genetic landscape, and current treatment strategies for DIPG.
- To highlight recent advancements in understanding DIPG tumorigenesis through genomic and molecular characterization.
- To explore novel therapeutic avenues and delivery strategies emerging from new DIPG models.
Main Methods:
- Review of clinical trial data and published literature on DIPG.
- Analysis of genomic and molecular profiling studies of DIPG tissue.
- Evaluation of in vitro and in vivo DIPG models for therapeutic development.
Main Results:
- Identification of key histone gene mutations, genetic drivers, and methylation changes in DIPG.
- Advancements in stereotactic biopsy techniques have increased tumor tissue availability for research.
- Development of diverse in vitro and in vivo models facilitates the exploration of new therapies.
Conclusions:
- Genomic and molecular insights are crucial for understanding DIPG tumorigenesis.
- Novel DIPG models are essential for testing new therapeutic strategies and drug delivery methods.
- Despite challenges, ongoing research into DIPG's genetic landscape and therapeutic targets offers hope for improved treatments.
